DAX-0,53 % EUR/USD-0,06 % Gold+0,47 % Öl (Brent)-0,80 %

Horizon TherapeuticsAktie

ISIN: IE00BQPVQZ61 | WKN: A12B8E | Symbol: HZNP
30,23
 
USD
02:00:00 Nasdaq
+0,73 %
+0,22 USD
Geldkurs 14:30:23
23,610 USD
200 Stk.
Briefkurs 14:30:23
36,60 USD
100 Stk.
Mehr Daten anzeigen

Horizon Therapeutics Chart

Neuigkeiten zur Horizon Therapeutics PLC Aktie

ZeitTitel
11.11.19

Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA (pegloticase injection) Strategy to Optimize Treatment Outcomes
08.11.19

The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace
06.11.19

Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results
05.11.19

Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019
04.11.19

Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
04.11.19

New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting
31.10.19

Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life
24.10.19

Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
24.10.19

New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting
17.10.19

FORTUNE and Great Place to Work Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year
17.10.19

Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
11.10.19

New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
10.10.19

For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”
09.10.19

Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019
08.10.19

New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
Hier Upload von Dokumenten / Links zum Wertpapier: Upload

Die neusten Nachrichten zu Horizon Therapeutics

ZeitTitel
11.11.19
Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA (pegloticase injection) Strategy to Optimize Treatment Outcomes
08.11.19
The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace
06.11.19
Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results
05.11.19
Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019
04.11.19
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
mehr Horizon Therapeutics Nachrichten »

Nachrichten aus der Branche Pharmaindustrie

ZeitTitel
15:00 Uhr
Masimo to Present at Stifel 2019 Healthcare Conference
15:00 Uhr
Exicure’s CEO David Giljohann Honored in Crain’s 40 Under 40 Class of 2019
14:30 Uhr
Millendo Therapeutics Reports Third Quarter 2019 Operating and Financial Results
14:30 Uhr
Cerus Corporation to Present at the Stifel 2019 Healthcare Conference
13:52 Uhr
Novo Nordisk: Q3-Ergebnisse im Rahmen der Erwartungen, Ausblick umsatzseitig präzisiert und erhöht - Aktienanalyse
mehr Branchennachrichten »

Indexzugehörigkeit von Horizon Therapeutics

WertpapierPerf. %
Nasdaq
+0,26
NASDAQ Biotechnology Index
+0,41
NYSE Biotechnology Index
+0,25
Dynamic Mid Cap Intellidex Index
+0,31
Dynamic Mid Cap Growth Intellidex Index
+0,51
NYSE Biotechnology Index (Total Return)
+0,25
Dynamic Market Intellidex Index
+0,03
NASDAQ Health Care Index
+0,41
Nasdaq US Multi Cap Growth Index
+0,36
Nasdaq DM Ex Korea Large Mid Cap Index Net Total Return
+0,15
Alle zugehörigen Indizes »

Aktienkurs Horizon Therapeutics A12B8E | IE00BQPVQZ61

BörsenplatzNasdaq
Letzter Kurs30,23USD
Performance+0,73 %
Kurszeit02:00:00
Eröffnung30,01USD
Tageshoch30,34USD
Tagestief29,77USD
Vortageskurs30,01USD
Volumen962,48 Tsd.Stk.
52-Wochen Hoch31,25USD
52-Wochen Tief17,960USD
Anzahl Trades6.198
Performance 1 Monat+10,90 %
Performance 1 Jahr+38,04 %

Stammdaten zu Horizon Therapeutics

NameHorizon Therapeutics PLC
KurznameHorizon Therap
NamenszusatzRegistered Shs
KategorieAktien
AktientypStammaktien
WKNA12B8E
ISINIE00BQPVQZ61
SymbolHZNP
BranchePharmaindustrie
LandIrland Irland
ReferenzwährungUSD
Aktienanzahl118,85 Mio.
Marktkapitalisierung3,59 Mrd.USD

Performance Horizon Therapeutics Aktie

ZeitKursPerf.
1 Tag30,23USD
+0,73 %
1 Woche29,85USD
+0,54 %
1 Monat27,06USD
+10,90 %
3 Monate26,22USD
+14,45 %
6 Monate28,05USD
+6,99 %
Lfd. Jahr19,540USD
+53,58 %
1 Jahr21,740USD
+38,04 %
3 Jahre20,300USD
+47,83 %
5 Jahre13,095USD
+129,17 %
mehr Performancedaten »
Adresse und Kontaktdaten
NameHorizon Therapeutics PLC
StadtDublin
LandIrland Irland
Aktionäre interessieren sich auch für:
#WertpapierPerf. %
1.
Centerra Gold
+0,37
2.
Geely Automobile Holdings
-2,03
3.
Infinity Pharmaceuticals
0,00
 
4.
GoGold Resources
+2,45
5.
Northern Vertex Mining
+1,86
6.
Tencent Holdings
-3,79
7.
Aben Resources
+0,22
8.
Group Ten Metals
+3,39
9.
TDH Holdings
-3,59
10.
Eldorado Gold
+1,44